SGMOQ — SANGAMO THERAPEUTICS, INC
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1001233 ·
Last close
$0.15
Market Cap
—
52W High
$0.76
52W Low
$0.03
ADV30
2,034,283
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,442,000 | — | -31,946,000 | -30,995,000 | 59,965,000 | 27,586,000 | 78,920,000 |
| Dec 2025 | 14,228,000 | — | -24,968,000 | -37,419,000 | 59,745,000 | 20,948,000 | 74,013,000 |
| Sep 2025 | 581,000 | — | -35,553,000 | -34,930,000 | 88,643,000 | 29,616,000 | 82,400,000 |
| Jun 2025 | 18,306,000 | — | -17,855,000 | -19,986,000 | 97,558,000 | 38,344,000 | 77,956,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-90,341,000
Investing CF
$-115,000
Financing CF
$89,314,000
CapEx
$-243,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-21
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,658,244,000
Inventory
—
Receivables
$6,364,000
ST Investments
$0
EBIT TTM
$-110,322,000
Pretax Income TTM
$-124,017,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 39,552,000 | -108,004,000 | -122,932,000 | 59,745,000 | 74,013,000 | -14,268,000 | -97,208,000 |
| Dec 2024 | 57,800,000 | -98,448,000 | -97,941,000 | 101,635,000 | 78,865,000 | 22,770,000 | -67,139,000 |
| Dec 2023 | 176,232,000 | -118,992,000 | -257,831,000 | 165,320,000 | 82,433,000 | 82,887,000 | -224,842,000 |
| Dec 2022 | 111,299,000 | -201,281,000 | -192,278,000 | 562,509,000 | 267,551,000 | 294,958,000 | -223,627,000 |
TTM Snapshot
Revenues TTM
$49,412,000
NetIncome TTM
$10,672,000
OpCashFlow TTM
$0
Assets (Latest)
$101,635,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $217.90B | $403.04 | — |
| GILD | GILEAD SCIENCES, INC. | $179.47B | $144.74 | — |
| MRNA | Moderna, Inc. | $75.86B | $190.01 | — |
| ARGX | ARGENX SE | $57.16B | $919.21 | — |
| RVMD | Revolution Medicines, Inc. | $44.29B | $206.64 | — |
News headlines (Yahoo Finance, 1h cache)
Fabry Disease Market Outlook: 6 Upcoming Therapies Set to Influence the Future Market Landscape | DelveInsight
2026-10-01 14:31 · Yahoo
PTC takes a chance on Sangamo’s Fabry disease gene therapy
2026-08-13 11:10 · Yahoo
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
2026-09-21 20:30 · Yahoo
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
2026-08-12 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.